Exosomes and Colon Cancer — What This Record Contains

This analysis was generated by Profoundd's AI strictly from the Medical Talks — Integrative & Longevity Medicine primary record and the labeled commentary, news, and critiques indexed alongside it — every claim is drawn from those sources, not from outside knowledge.

Question examined: exosomes for colon cancer

Exosomes and Colon Cancer — What This Record Contains

Direct answer: The passages in this archive touch on exosomes and on colon cancer, but they do not directly address exosomes as a treatment for colon cancer. The two topics appear in separate contexts. Here is exactly what the record shows on each, and where they do — and do not — intersect.

What the Record Says About Exosomes

Exosomes appear in three passages, all in the context of regenerative medicine and anti-aging, not oncology treatment.

Dr. Frank Shallenberger (2021) describes exosomes as the active signaling molecules released by stem cells — the mechanism by which stem cells communicate and trigger local tissue repair. He states the current understanding is that "stem cells are just sort of the transport vehicle for the exosomes — it's the exosomes that are really doing the healing." He describes injecting exosomes for regenerative purposes and notes pre-treating with ozone therapy to upregulate mitochondrial function before administering exosomes or stem cells [11, 8].

Dr. Edward Park (2024) addresses exosomes and cancer directly — but as a caution, not a treatment. He states that exosomes promote new blood vessel generation (angiogenesis), which is also a mechanism of metastasis, and that for this reason practitioners "generally say no" to exosomes in patients with active, undiagnosed, or unresolved cancer. He notes the consent language warns against use with undiagnosed cancer. He acknowledges anecdotes of people whose cancer improved after exosomes, but frames this as the opposite of the chemotherapy mechanism rather than as evidence of efficacy: "it's just more of a caution thing." He does not cite studies on exosomes treating cancer [10].

Dr. Park (2026) describes the mechanism of exosome action via microRNA — blocking tonic inhibitors of differentiation so local cells temporarily "act like a child" and regenerate. He notes this is also relevant to cancer biology as a defense mechanism, but does not develop this into a treatment claim [16].

Dr. Park (2026, separate passage) describes exosomes as more predictable and less inflammatory than PRP or stem cells for local injection (e.g., knee problems), and notes they shut down inflammation rather than promoting it [18].

What the Record Says About Colon Cancer

Colon cancer appears across multiple passages, in several distinct contexts:

• Rising incidence in younger people: Dr. William Makis (2025) describes an observed increase in colon cancers presenting in people in their 20s and 30s, which he characterizes as part of a broader pattern of aggressive cancers in younger cohorts. He notes the mainstream oncology response has been to debate lowering the screening age, and argues the more important question is investigating the underlying pathophysiology [1, 14, 17].

• Temporal correlation with COVID/vaccines: Makis discusses the contested question of whether COVID infection or COVID vaccination could be causally related to this pattern, acknowledging the argument that colon cancer "takes many years to develop" and that temporal correlations are not clear-cut [3].

• Repurposed drugs: Mebendazole (an FDA-approved antiparasitic) is described as having active clinical trials in colon cancer and prostate cancer in adults, and brain cancer in children. The proposed mechanism relevant to colon cancer is blockade of glucose transporters on cancer cells, starving them of fuel [4, 6]. Ivermectin is described as having been tested against 28 cancer types in a Mexican research group's pre-clinical work, with colon cancer among the responders (though not the top responder) [7].

• Mitochondrial dysfunction: A 2015 Riordan Clinic presentation describes peer-reviewed research showing that overexpressing the protein frataxin in colon cancer cell lines improved mitochondrial function and inhibited cancer growth — consistent with Warburg's hypothesis that cancer cells suppress mitochondrial oxidative metabolism [2, 5, 9].

• Anecdotal clinical reports: A PA-C (Sarah Green) describes a patient with colon cancer metastatic to the liver whose tumor markers became "almost non-existent" using a protocol that appears to include repurposed drugs discussed with Dr. Paul Marik, though the specific protocol is not detailed in the passage [13].

• Microplastics: A 2026 Malone News piece cites Stanford research linking microplastics to elevated cancer risk, specifically naming colon cancer, via oxidative stress, DNA damage, gut microbiome disruption, and endocrine disruption [15].

Where Exosomes and Colon Cancer Intersect in This Record

They do not directly intersect. No passage in this archive describes exosomes being used to treat colon cancer, proposes exosomes as a colon cancer therapy, or cites studies on exosomes in colon cancer patients or cell lines.

The closest the record comes is Dr. Park's caution [10]: exosomes are not recommended for patients with active cancer precisely because the angiogenic properties of exosomes could theoretically promote tumor growth or metastasis — the opposite of a therapeutic framing. He acknowledges anecdotes of improvement but does not present them as evidence of efficacy.

What Is Not in This Record

• No peer-reviewed studies on exosomes as a colon cancer treatment are cited or described in these passages.
• No clinical trials, case series, or pre-clinical data on exosomes in colon cancer appear here.
• No practitioner in these passages recommends exosomes for colon cancer.

The absence of such evidence in this archive does not establish that no such research exists — it means this particular record does not contain it. Anyone researching this question would need to consult primary literature (e.g., PubMed searches on exosome colon cancer, or the exosome conference literature Dr. Park references [16]) directly.

Summary

This archive discusses exosomes (regenerative/anti-aging context) and colon cancer (rising incidence, repurposed drugs, mitochondrial biology, microplastics) as separate topics. They do not meet as a treatment pairing in any passage here. The one practitioner who addresses the exosome-cancer intersection [10] frames it as a contraindication to be cautious about, not a therapeutic opportunity — while leaving open that anecdotes exist on both sides.

Sources cited

1. [1] (Record) Turbo cancers and repurposed drugs, Dr Makis
2. [2] (Record) Oxygen, Mitochondria, ATP and Origins of Cancer (Riordan Clinic)
3. [3] (Record) Turbo cancers and repurposed drugs, Dr Makis
4. [4] (Record) Turbo cancers and repurposed drugs, Dr Makis
5. [5] (Record) Oxygen, Mitochondria, ATP and Origins of Cancer (Riordan Clinic)
6. [6] (Record) Repurposed drugs for cancers
7. [7] (Record) Bombshell Interview with Dr William Makis on Using IVERMECTIN and FENBENDAZOLE to Treat/Cure Cancer
8. [8] (Record) Mitochondria & Anti-Aging w/ Dr. Frank Shallenberger (RWN #118)
9. [9] (Record) Oxygen, Mitochondria, ATP and Origins of Cancer (Riordan Clinic)
10. [10] (Record) Dr. Ed Park - Anti-Aging & Healing With Exosomes (The Trail To Health Ep 27)
11. [11] (Record) Mitochondria & Anti-Aging w/ Dr. Frank Shallenberger (RWN #118)
12. [12] (Record) Fasting for Cancer? Dr. William Makis - Ivermectin and Fenbendazole
13. [13] (Record) A Conversation with Sarah Green PA-C, Dr. Paul Marik | Ivermectin, Cancer & Spike Protein
14. [14] (Record) Turbo cancers and repurposed drugs, Dr Makis
15. [15] (Record) You Are Eating Plastic. Every Single Day.
16. [16] (Record) Exosomes are the Songs of Healing — Dr. Edward Park & Dr. Achina Stein
17. [17] (Record) Turbo cancers and repurposed drugs, Dr Makis
18. [18] (Record) How To Avoid Aging Through Telomere Activation with Edward Park (Make Peace with Food)